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Summary Introduction Cetuximab is registered for use in
colorectal cancer (CRC) patients with RAS wild-type tumours
only. Simvastatin blocks the mevalonate pathway and thereby
interferes with the post-translational modification
(prenylation) of KRAS. We hypothesize that the activitated
KRAS pathway in KRAS mutant tumors can be inhibited by
simvastatin rendering these tumors sensitive to the EGFR in-
hibitor cetuximab. Methods A Simon two-stage, single-arm,
phase II study was performed to test the efficacy and safety of
the addition of simvastatin to cetuximab in patients with a
KRAS mutation in their CRC tumour who were previously
treated with fluoropyrimidine, oxaliplatin and irinotecan
based regimens. The primary endpoint was to test the percent-
age of patients alive and free from progression 12.5 weeks
after the first administration of cetuximab. Our hypothesis
was that at least 40 % was free from progression, comparable
to, though slightly lower than in KRAS wild-type patients.
Results Four of 18 included patients (22.2 %) were free from
progression at the primary endpoint time. The time to
progression in these 4 patients ranged from 20.3 to 47 weeks.
Conclusion Based on the current study we conclude that the
theoretical concept of KRAS modulation with simvastatin
was not applicable in the clinic, as we were not able to restore
sensitivity to cetuximab in CRC patients harbouring a somatic
KRAS mutation.
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Introduction
Each year over 940.000 patients are diagnosed with colorectal
cancer (CRC) world-wide and over 500.000 people die of this
disease [1]. In patients with advanced or metastatic colorectal
treatment with monoclonal antibodies directed against the epi-
dermal growth factor receptor (EGFR), cetuximab and
panitumumab are proven to be active after failing
fluoropyrimidine, oxaliplatin and irinotecan based regimens,
though only in patients with tumours without a mutation in the
KRAS [2, 3] or more recently RAS gene [4]. This led to the
question whether increased activation of KRAS signaling by
KRAS mutations can be modulated, thereby making KRAS
mutated tumours sensitive to EGFR inhibitor therapy. One
possible target for modulation is the mevalonate pathway, as
we have previously discussed [5].
The mevalonate pathway is a metabolic cascade with var-
ious end-products including cholesterol. Other end-products
are farnesyl and geranylgeranyl moieties (C15 and C17), both
essential for posttranslational prenylation of the RAS protein
and its association with the cytoplasmic membrane, and there-
by activation of the RAS protein. By using HMG-CoA reduc-
tase inhibitors not only the synthesis of cholesterol is
inhibited, but also the formation of C15 and C17, thereby
inhibiting posttranslational modification of RAS [5, 6]. By
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blocking the mevalonate pathway in CRC patients with KRAS
mutated tumours, the activated KRAS pathway might be
inhibited. This would theoretically lead to increased sensitiv-
ity to cetuximab, potentially comparable to tumours with
wild-type KRAS.
This single-arm, phase II study was designed to test the
safety and efficacy of the addition of simvastatin to cetuximab
in patients with a KRAS mutation in their tumour who were




Eligible patients had advanced or metastatic colorectal cancer
with a mutation in codon 12, 13 or 61 of theKRAS gene (either
on tissue of the primary tumour or of a metastasis), after fail-
ing fluoropyrimidine, oxaliplatin and irinotecan based regi-
mens, or after failure of oxaliplatin based therapy in patients
who cannot be treated with irinotecan.
Other eligibility criteria included age 18 years or older,
written informed consent, World Health Organisation
(WHO) performance score of 0 to 2 and progression of disease
in the past 3 months prior to inclusion. Exclusion criteria
included symptomatic brain metastases, previous treatment
with EGFR inhibitors and history of toxicity during statin.
The study protocol was approved by the Ethics
Committees of all participating hospitals.
Study design
This phase II, single-arm, multi-center study was performed
using a Simon two-stage design [7]. In the first stage, 15
patients were included, followed by an interim analysis.
Results of this analysis would determine whether the combi-
nation of simvastatin and cetuximab may have clinical benefit
in this group of CRC patients, thus justifying the second stage
and including up to 41 patients.
Treatment schedule
Cetuximab was first administered at least one week after start
of simvastatin therapy. The initial cetuximab dose was
400 mg/m2 with subsequent weekly infusions of 250 mg/m2.
Pretreatment with an antihistamine and a corticosteroid was
mandatory before the first infusion of cetuximab and recom-
mended for all subsequent infusions.
Simvastatin 80 mg orally once daily was started at start of
study participation. This dose was chosen taken into consid-
eration the need for continuous administration of the statin
during the entire study, inhibitory effect on the mevalonate
pathway and tolerability. Statins in cancer therapy have been
studied in clinical trials in solid [8–18] and haematologic
[19–21] malignancies, both as monotherapy as well as addi-
tional to chemotherapy. Statin doses from 20 mg/day up to
35 mg/kg/day were used, with only continuous use of statins
when dosed at a maximum of 80 mg/day. Since the aim of this
study is to modulate KRAS during the entire treatment with
cetuximab and therefore a continuous exposure to simvastatin
is needed, a dose of 80 mg/day was selected in order to obtain
maximum effect while minimizing the risk of toxicity.
Treatment was continued until progression of disease, clin-
ical signs of progression, unacceptable toxicity or cetuximab
toxicity requiring withholding of more than 2 subsequent
infusions.
Tumour response was every 6 weeks using CT-scans and
according to Response Evaluation Criteria In Solid Tumors
(RECIST) version 1.1. Scans of patients free from progression
at time of primary endpoint were centrally reviewed.
Endpoints
Primary objective was to test the percentage of patients alive
and free from progression and alive at 12.5 weeks after the
first administration of cetuximab. Our hypothesis was that at
least 40 % of patients was free from progression, comparable
to though slightly lower than in KRAS wild-type patients [2].
Secondary objectives were to investigate overall survival
(OS), objective response rate (ORR), progression free survival
(PFS), and safety of simvastatin combined with cetuximab in
this population and to evaluate the correlation between skin
toxicity and response to treatment. Exploratory endpoints
were to investigate the role of cholesterol as a biomarker dur-
ing this treatment and whether PIK3CA status correlates with
response to cetuximab in this population.
Mutational analysis
KRAS mutational status was reconfirmed centrally, testing for
the 7 most frequent mutations in codon 12 and 13 as described
in detail elsewhere [22]. In addition, we tested for the 3 most
common mutation in the PIK3CA gene; in exon 9
(c.1624G>A (p.E542K) and c.1633G>A (pE545K)) and exon
20 (c.3140A>G (p.H1047R)). Though KRAS and BRAF mu-
tations are known to be mutually exclusive [23], we did test
for the activating hotspot mutation p.V600E.
Statistics
Sample size was chosen based on previous published data of
CRC patients with KRAS wild-type tumours treated with
cetuximab [2], aiming for a at least 40 % of patients free from
progression at 12.5 weeks after start of cetuximab treatment in
patients with KRAS mutant type tumours (i.e., slightly lower
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than the effect inKRASwild-type patients). Combined with an
alpha of 0.05 and a power of 0.80, an interim size of 15 and a
total sample size of 46 patients were required. An interim
analysis was to be performed after the inclusion of 15
evaluable patients. Only when at least 40 % (i.e., 6 patients)
were free from progression at the 12.5 weeks, another 31




During the first stage of the study 18 instead of 15 patients
were enrolled to account for patients that were thought to
unevaluable for the primary endpoint. Baseline characteristics
are listed in Table 1. None of the patients were using statins
prior to inclusion.
Efficacy
Four of 18 patients were free from progression at the primary
endpoint time, therefore the percentage of patients alive and
free from progression 12.5 weeks after the first administration
of cetuximab was 22 %. The time to progression in these 4
patients ranged from 20.3 to 47 weeks. Drug exposure to
simvastatin and cetuximab was equal for all patients.
Figure 1 shows progression free (panel A) and overall sur-
vival (panel B). Median PFS was 9 weeks (mean 12.9 weeks,
range 3.9–47 weeks). Median OSwas 31.5 weeks (mean 36.3,
range 8–138.1). The ORR was 6 % (partial remission in 1
patient). A true relation between skin toxicity and efficacy of
treatment was not observed in this study though this may
(partly) be due to the low number of patients and due to the
improved knowledge of the efficacy of pre-emptive skin tox-
icity management.
Safety
Main symptoms and adverse events reported on study report-
ed were fatigue (n=11), acne (n=10) and rash (n=6).
Myopathy was not reported. Three patients had elevation of
creatine kinase (CK) levels on study (grade 4 in one patient).
Skin toxicity occurred in 10 patients; the worst grade of
acneiform rashwas grade 3 in one patient, grade 2 in 4 patients
and grade 1 in the remaining 5 patients. One patient experi-
enced a severe (i.e., grade 3) allergic reaction during the first
infusion of cetuximab. One of the serious adverse events did
precede the death of a participant. Upon the scheduled labo-
ratory examination severe elevation of liver enzymes were
observed. Rhabdomyolysis was considered, (though on study
CK levels were below 3.000 U/l) and so was progression of
liver metastases. Study medication was interrupted immedi-
ately, however the patient’s situation did not improve and it
was decided to terminate study participation permanently.
Specific SNPs associated with increased risk of statin-
induced myopathy (i.e., SLCO1B1 variants [24]) were consid-
ered though none were identified in this patient. The patient
deceased few weeks later. Post-mortem examination did not
occur.
Exploratory endpoints
All patients showed cholesterol reduction, ranging from a
maximum reduction of 0.8 to 64.4 %. The percentage of cho-
lesterol reduction did not correlate with progression free
survival.
Tumour tissue of 15 patients was available for central re-
view. Table 2 shows mutational status of KRAS and PIK3CA
per patient. Of the 4 patients responding to treatment, 3 had a
KRASmutation in codon 12 and 1 had a PIK3CAmutation. As
expected all patients were BRAF wild-type.
Discussion
To our knowledge, this is the first clinical trial testing the
addition of simvastatin to cetuximab monotherapy in CRC
patients harbouring a KRAS mutation in tumour tissue as an
attempt to restore cetuximab sensitivity. While it was remark-
able to notice a durable progression free survival in 4 patients,
the interim analysis showed that the predefined criteria to pro-
ceed to the second stage of this study were not reached.
Table 1 Baseline
characteristics Age – years
Mean 62
Range 52–75
Gender – n (%)
Male 13 (72)
Female 5 (18)
WHO performance score – n (%)
0 13 (72)
I 5 (18)
Site of primary tumour – n (%)
Colon 12 (67)
Rectum 6 (33)




Prior surgery – n (%) 13 (72)
Prior radiotherapy – n (%) 4 (22)
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Therefore, the current study suggests that high dose simvastat-
in does not render cetuximab sensitivity in KRAS mutant
CRC.
Statines are one of several potential agents to modulate
KRAS signaling, as we have previously reviewed [5]. The
current study is not the first to hypothesize on statins and their
inhibitory effect on the activity of RAS and its downstream
pathway. However, all but one previous reports include only
preclinical data. For example, lovastatin and simvastatin in-
hibit downstream activity in breast cells with mutated HRAS,
possibly by inhibiting membrane localization of HRAS. The
effect was reversed when adding farnesyl pyrophosphate, in-
dicating the effect was related to prenylation of RAS [25].
More recently, simvastatin was shown to restore cetuximab
resistance in vitro and in vivo [26]. Based on these results,
one might wonder whether the negative outcome of the cur-
rent study would have been different if using higher doses of
simvastatin. However, preclinical data showed a significant
reduction in cell growth of KRASmutant CRC cell lines using
0.2 μM simvastatin, the equivalent of 2 mg/kg/day in humans
[26]. Moreover, in cardiovascular disease the registered dose
of 80 mg of simvastatin is significantly lowers cholesterol
serum levels. It is reasonable that this dose will also affect
the formation of the C15 and C17 groups and subsequently
the prenylation of the KRAS protein. Furthermore, we ques-
tion whether higher doses will be feasible in terms of safety.
A recent study of Lee et al. tested the efficacy of the addi-
tion of the same dose of simvastatin (i.e., 80 mg once daily) to
cetuximab and irinotecan in KRAS mutant CRC patients fail-
ing prior oxaliplatin, fluoropyrimidine and irinotecan based
therapy [27]. The initially reported PFS and OS (median
7.6 months and 12.8 months respectively) were considerably
higher than historical results in chemotherapy refractory CRC
patients with KRAS mutated tumours [28] and chemotherapy
refractory CRC patients in general [29–31]. Moreover, these
results were in contrast with our findings. However, a recent
erratum published by this group showed that initial survival
data were incorrect [32]. The corrected PFS and OS are in line
with our results, providing no evidence for a modulating effect
of simvastatin on the KRAS mutant phenotype.
The majority of patients had a KRASmutation in codon 12
and only 3 in codon 13. It has been reported that tumours
harbouring a G13D mutation in the KRAS gene might be sen-
sitive to EGFR-inhibitors [33]. Moreover, none of our patients
had a PIK3CAmutation in exon 20, while these might also be
more likely to be sensitive to EGFR-inhibitors, contrary to
mutations in exon 9 [34]. However, of the 4 patients who were
free from progression at time of the primary endpoint only one
patients had a G13D mutation in the KRAS gene and none had
a PIK3CA mutation in exon 20.
Conclusion
Based on the current study we conclude that the concept of
KRAS modulation with simvastatin was not applicable in the
clinic. Similar results were recently demonstrated in this
Fig. 1 a Progression free
survival in weeks for the addition
of simvastatin to cetuximab in
CRC patients failing standard
therapy. b Overall survival in
weeks for the addition of
simvastatin to cetuximab in CRC
patients failing standard therapy
Table 2 KRAS and PIK3CA mutational status per patient

















17 G13D Mutation in exon 9
18 G12D Mutation in exon 9
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population treated with panitumumab and simvastatin [35].
Better treatment strategies are needed for this patient
population.
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